Intuitive Surgical (ISRG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intuitive Surgical's SP platform is gaining traction as a cost-efficient, high-throughput option for ASCs, complementing da Vinci 5 in hospitals.
Intuitive Surgical, Inc. (ISRG) concluded the recent trading session at $452.35, signifying a +2.11% move from its prior day's close.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Intuitive Surgical's SP platform secures new colorectal clearances, with 88% growth in procedures and rising global adoption momentum.
Intuitive Surgical, Inc. (ISRG) concluded the recent trading session at $447.23, signifying a +1.82% move from its prior day's close.
Zacks.com users have recently been watching Intuitive Surgical (ISRG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The market has performed strongly over the past year, with the S&P 500 continuing to reach new all-time highs. Despite this, several well-known names are down big from their 52-week highs.
Intuitive Surgical unveils real-time surgical insights on its da Vinci 5, enhancing precision, safety, and efficiency with advanced software features.
Intuitive Surgical stock (NASDAQ: ISRG) has dropped 16% this year, notably lagging behind the S&P 500's 10% increase. The stock has experienced downward pressure recently after management indicated that potential tariffs may adversely affect its performance in 2026.
Intuitive Surgical, Inc. (NASDAQ:ISRG ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 9:30 AM EDT Company Participants David Rosa - CEO & Director Jamie Samath - CFO, Head of Business Technology & Enterprise Technology Leader Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device Equity Research Analyst All right. Good morning, everyone.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?